Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 1
2016 4
2019 3
2020 4
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype.
Fairfield H, Dudakovic A, Khatib CM, Farrell M, Costa S, Falank C, Hinge M, Murphy CS, DeMambro V, Pettitt JA, Lary CW, Driscoll HE, McDonald MM, Kassem M, Rosen C, Andersen TL, van Wijnen AJ, Jafari A, Reagan MR. Fairfield H, et al. Among authors: hinge m. Cancer Res. 2021 Feb 1;81(3):634-647. doi: 10.1158/0008-5472.CAN-20-1088. Epub 2020 Nov 20. Cancer Res. 2021. PMID: 33218968 Free PMC article.
Strategies to improve patient-reported outcome completion rates in longitudinal studies.
Nielsen LK, King M, Möller S, Jarden M, Andersen CL, Frederiksen H, Gregersen H, Klostergaard A, Steffensen MS, Pedersen PT, Hinge M, Frederiksen M, Jensen BA, Helleberg C, Mylin AK, Abildgaard N. Nielsen LK, et al. Among authors: hinge m. Qual Life Res. 2020 Feb;29(2):335-346. doi: 10.1007/s11136-019-02304-8. Epub 2019 Sep 23. Qual Life Res. 2020. PMID: 31549365 Free PMC article.
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study.
Nielsen LK, Stege C, Lissenberg-Witte B, van der Holt B, Mellqvist UH, Salomo M, Bos G, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden A, Deenik W, Coenen J, Hinge M, Klein S, Tanis B, Szatkowski D, Brouwer R, Westerman M, Leys R, Sinnige H, Haukås E, van der Hem K, Durian M, Gimsing P, van de Donk N, Sonneveld P, Waage A, Abildgaard N, Zweegman S. Nielsen LK, et al. Among authors: hinge m. Haematologica. 2020 Jun;105(6):1650-1659. doi: 10.3324/haematol.2019.222299. Epub 2019 Sep 12. Haematologica. 2020. PMID: 31515355 Free PMC article. Clinical Trial.
Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients.
Hinge M, Andersen KT, Lund T, Jørgensen HB, Holdgaard PC, Ormstrup TE, Østergaard LL, Plesner T. Hinge M, et al. Haematologica. 2016 Oct;101(10):e415-e418. doi: 10.3324/haematol.2016.146092. Epub 2016 Jul 6. Haematologica. 2016. PMID: 27390357 Free PMC article. Clinical Trial. No abstract available.
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma.
Andersen KT, Hinge M, Szabo AG, Segel E, Ormstrup T, Holdgaard PC, Pallisgaard N, Kerndrup G, Plesner T. Andersen KT, et al. Among authors: hinge m. Clin Hematol Int. 2020 Jan 26;2(1):35-39. doi: 10.2991/chi.d.200116.001. eCollection 2020 Mar. Clin Hematol Int. 2020. PMID: 34595441 Free PMC article. No abstract available.
12 results